从一名接受氧氟沙星治疗的复发性呼吸道感染患者分离出的流感嗜血杆菌菌株中喹诺酮耐药性增加。
Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.
作者信息
Vila J, Ruiz J, Sanchez F, Navarro F, Mirelis B, de Anta M T, Prats G
机构信息
Departament de Microbiologia, Institut de Investigació Biomédica August Pi i Sunyer, Hospital Clínic, Facultat de Medicina, Universitat de Barcelona, 08036 Barcelona, Spain.
出版信息
Antimicrob Agents Chemother. 1999 Jan;43(1):161-2. doi: 10.1128/AAC.43.1.161.
Abstract
The increase in the level of quinolone resistance of Haemophilus influenzae clinical isolates during ofloxacin therapy of a patient with recurrent respiratory infections was investigated. The first isolate (MIC of ciprofloxacin of 2 microg/ml) and the second isolate (MIC of 32 microg/ml) belonged to the same clone, as shown by pulsed-field gel electrophoresis, and the increase in the resistance level was associated with a substitution in Ser-84 to Arg in the ParC protein. These results emphasize the potential risk of development of quinolone-resistant H. influenzae during fluoroquinolone therapy in patients with recurrent respiratory infection.
摘要
对一名复发性呼吸道感染患者进行氧氟沙星治疗期间，流感嗜血杆菌临床分离株喹诺酮耐药水平的增加情况进行了调查。如脉冲场凝胶电泳所示，首个分离株（环丙沙星的最低抑菌浓度为2微克/毫升）和第二个分离株（最低抑菌浓度为32微克/毫升）属于同一克隆，耐药水平的增加与ParC蛋白中第84位丝氨酸替换为精氨酸有关。这些结果强调了复发性呼吸道感染患者在氟喹诺酮治疗期间发生耐喹诺酮流感嗜血杆菌的潜在风险。
相似文献
1
Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.从一名接受氧氟沙星治疗的复发性呼吸道感染患者分离出的流感嗜血杆菌菌株中喹诺酮耐药性增加。
Antimicrob Agents Chemother. 1999 Jan;43(1):161-2. doi: 10.1128/AAC.43.1.161.
2
Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.不可分型流感嗜血杆菌临床分离株中氟喹诺酮耐药性的分子特征
Antimicrob Agents Chemother. 2015 Jan;59(1):461-6. doi: 10.1128/AAC.04005-14. Epub 2014 Nov 10.
3
A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.环丙沙星和左氧氟沙星与其他药物针对呼吸道病原体的活性比较。
J Chemother. 1998 Aug;10(4):276-9. doi: 10.1179/joc.1998.10.4.276.
4
Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY antimicrobial surveillance program (North and Latin America).耐氟喹诺酮类流感嗜血杆菌：哨兵抗菌药物监测计划（北美和拉丁美洲）中确诊菌株的发生率及分析
Diagn Microbiol Infect Dis. 2000 Apr;36(4):255-9. doi: 10.1016/s0732-8893(00)00110-3.
5
In vitro antibacterial activities of new fluoroquinolones against clinical isolates of haemophilus influenzae with ciprofloxacin-resistance-associated alterations in GyrA and ParC.新型氟喹诺酮类药物对具有环丙沙星耐药相关GyrA和ParC改变的流感嗜血杆菌临床分离株的体外抗菌活性。
Chemotherapy. 2004 Dec;50(6):265-75. doi: 10.1159/000082624. Epub 2004 Dec 8.
6
Levofloxacin treatment failure in Haemophilus influenzae pneumonia.流感嗜血杆菌肺炎中左氧氟沙星治疗失败
Emerg Infect Dis. 2003 Nov;9(11):1475-8. doi: 10.3201/eid0911.030176.
7
Quinolone-resistant Haemophilus influenzae in a long-term care facility: clinical and molecular epidemiology.长期护理机构中耐喹诺酮类流感嗜血杆菌：临床与分子流行病学
Clin Infect Dis. 2004 Jun 1;38(11):1564-9. doi: 10.1086/420820. Epub 2004 May 12.
8
Microbial virulence, molecular epidemiology and pathogenic factors of fluoroquinolone-resistant Haemophilus influenzae infections in Guangzhou, China.中国广州地区氟喹诺酮类耐药流感嗜血杆菌感染的微生物毒力、分子流行病学和致病因子。
Ann Clin Microbiol Antimicrob. 2018 Nov 23;17(1):41. doi: 10.1186/s12941-018-0290-9.
9
Serotype distribution and beta-lactam resistance in Haemophilus influenzae isolated from patients with respiratory infections in Korea.韩国呼吸道感染患者分离的流感嗜血杆菌血清型分布及对β-内酰胺类药物的耐药性
J Microbiol. 2010 Feb;48(1):84-8. doi: 10.1007/s12275-009-0212-9. Epub 2010 Mar 11.
10
Susceptibility of Canadian isolates of Haemophilus influenzae, Moraxella catarrhalis and Streptococcus pneumoniae to oral antimicrobial agents.加拿大分离出的流感嗜血杆菌、卡他莫拉菌和肺炎链球菌对口服抗菌药物的敏感性。
Int J Antimicrob Agents. 2001 Jun;17(6):457-64. doi: 10.1016/s0924-8579(01)00334-x.
引用本文的文献
1
Unusual and Unconsidered Mechanisms of Bacterial Resilience and Resistance to Quinolones.细菌对喹诺酮类药物产生耐受性和耐药性的异常及未被重视的机制
Life (Basel). 2024 Mar 14;14(3):383. doi: 10.3390/life14030383.
2
Outcomes of respiratory viral-bacterial co-infection in adult hospitalized patients.成年住院患者呼吸道病毒-细菌合并感染的结局
EClinicalMedicine. 2021 Jun 10;37:100955. doi: 10.1016/j.eclinm.2021.100955. eCollection 2021 Jul.
3
In Vitro Anti-NTHi Activity of Haemophilin-Producing Strains of .产嗜血菌素菌株的体外抗嗜肺军团菌活性 。
你提供的原文似乎不太完整，“of”后面缺少具体内容。以上是根据现有内容翻译的结果 。
Pathogens. 2020 Mar 25;9(4):243. doi: 10.3390/pathogens9040243.
4
Transferable Mechanisms of Quinolone Resistance from 1998 Onward.1998 年以来喹诺酮类耐药的可转移机制。
Clin Microbiol Rev. 2019 Aug 14;32(4). doi: 10.1128/CMR.00007-19. Print 2019 Sep 18.
5
Microbial virulence, molecular epidemiology and pathogenic factors of fluoroquinolone-resistant Haemophilus influenzae infections in Guangzhou, China.中国广州地区氟喹诺酮类耐药流感嗜血杆菌感染的微生物毒力、分子流行病学和致病因子。
Ann Clin Microbiol Antimicrob. 2018 Nov 23;17(1):41. doi: 10.1186/s12941-018-0290-9.
6
Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates.不可分型流感嗜血杆菌临床分离株中氟喹诺酮耐药性的分子特征
Antimicrob Agents Chemother. 2015 Jan;59(1):461-6. doi: 10.1128/AAC.04005-14. Epub 2014 Nov 10.
7
Gyramides prevent bacterial growth by inhibiting DNA gyrase and altering chromosome topology.细菌旋转酶抑制剂通过抑制 DNA 旋转酶和改变染色体拓扑结构来阻止细菌生长。
ACS Chem Biol. 2014 Jun 20;9(6):1312-9. doi: 10.1021/cb500154m. Epub 2014 Apr 22.
8
Global fluoroquinolone resistance epidemiology and implictions for clinical use.全球氟喹诺酮类药物耐药性流行病学及其临床应用意义
Interdiscip Perspect Infect Dis. 2012;2012:976273. doi: 10.1155/2012/976273. Epub 2012 Oct 14.
9
Melting curve analysis for rapid detection of topoisomerase gene mutations in Haemophilus influenzae.用于快速检测流感嗜血杆菌中拓扑异构酶基因突变的熔解曲线分析
J Clin Microbiol. 2009 Mar;47(3):781-4. doi: 10.1128/JCM.01645-08. Epub 2009 Jan 7.
10
Comparative efficacies of different antibiotic treatments to eradicate nontypeable Haemophilus influenzae infection.不同抗生素治疗方案根除非分型流感嗜血杆菌感染的疗效比较
BMC Infect Dis. 2008 Feb 7;8:15. doi: 10.1186/1471-2334-8-15.
本文引用的文献
1
In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis.新型8-甲氧基喹诺酮BAY 12-8039与六种氟喹诺酮对肺炎链球菌、流感嗜血杆菌和卡他莫拉菌的体外活性比较。
Antimicrob Agents Chemother. 1997 Jul;41(7):1594-7. doi: 10.1128/AAC.41.7.1594.
2
Isolation and characterization of a ciprofloxacin-resistant isolate of Haemophilus influenzae from The Netherlands.从荷兰分离并鉴定出一株耐环丙沙星的流感嗜血杆菌。
J Antimicrob Chemother. 1997 Feb;39(2):292-3. doi: 10.1093/jac/39.2.292.
3
Long-term persistence of ciprofloxacin-resistant Haemophilus influenzae in patients with cystic fibrosis.环丙沙星耐药性流感嗜血杆菌在囊性纤维化患者中的长期持续存在。
J Infect Dis. 1996 Dec;174(6):1345-7. doi: 10.1093/infdis/174.6.1345.
4
Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.喹诺酮耐药性大肠埃希菌临床分离株中parC基因突变的检测
Antimicrob Agents Chemother. 1996 Feb;40(2):491-3. doi: 10.1128/AAC.40.2.491.
5
Ciprofloxacin-resistant Haemophilus influenzae strains possess mutations in analogous positions of GyrA and ParC.耐环丙沙星的流感嗜血杆菌菌株在GyrA和ParC的类似位置存在突变。
Antimicrob Agents Chemother. 1996 Jul;40(7):1741-4. doi: 10.1128/AAC.40.7.1741.
6
Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease.一名慢性肺病患者的耐环丙沙星流感嗜血杆菌感染
Ann Pharmacother. 1993 Mar;27(3):309-10. doi: 10.1177/106002809302700311.
7
Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs.耐环丙沙星的大肠埃希菌临床分离株gyrA基因双突变与最低抑菌浓度之间的关联
Antimicrob Agents Chemother. 1994 Oct;38(10):2477-9. doi: 10.1128/AAC.38.10.2477.
8
Detection of quinolone resistance in Haemophilus spp.嗜血杆菌属中喹诺酮耐药性的检测
J Antimicrob Chemother. 1994 Nov;34(5):841-4. doi: 10.1093/jac/34.5.841.
9
Endogenous and exogenous reinfections by Haemophilus influenzae in patients with chronic obstructive pulmonary disease: the effect of antibiotic treatment on persistence.慢性阻塞性肺疾病患者中流感嗜血杆菌的内源性和外源性再感染：抗生素治疗对持续感染的影响
J Infect Dis. 1990 Mar;161(3):512-7. doi: 10.1093/infdis/161.3.512.
10
Persistence of Pseudomonas aeruginosa during ciprofloxacin therapy of a cystic fibrosis patient: transient resistance to quinolones and protein F-deficiency.
J Antimicrob Chemother. 1990 Jun;25(6):995-1010. doi: 10.1093/jac/25.6.995.
Zotero 插件